Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 9, 2005, Pages 3663-3667

  Nouér, Simone Aranha ^a   Nucci, Marcio ^a   De Oliveira, Márcia P ^a   Pellegrino, Flávia Lúcia Piffano Costa ^a   Moreira, Beatriz Meurer ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFEPIME; METALLO BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BLA SPM GENE; BRAZIL; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; MALE; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SCHOOL CHILD; SURGICAL WOUND; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHILD; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS;

EID: 24144464271     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.9.3663-3667.2005     Document Type: Article

References (41)

1. Andrade, S. S., R. N. Jones, A. C. Gales, and H. S. Sader. 2003. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J. Antimicrob. Chemother. 52:140-141.
2. Arruda, E. A., I. S. Marinho, M. Boulos, S. I. Sinto, H. H. Caiaffa, C. M. Mendes, C. P. Oplustil, H. Sader, C. E. Levy, and A. S. Levin. 1999. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol. 20:620-623.
3. Baddour, L. M., D. V. Hicks, M. M. Tayidi, S. K. Roberts, E. Walker, R. J. Smith, D. S. Sweitzer, J. A. Herrington, and B. G. Painter. 1995. Risk factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital. Microb. Drug Resist. 1:219-222.
4. Cailleaux, V., B. Mulin, G. Capellier, M. C. Julliot, M. Thouverez, and D. Talon. 1997. Epidemiological study of variations in beta-lactam antibiotic susceptibility of Pseudomonas aeruginosa in two intensive care units. J. Hosp. Infect. 37:217-224.
5. Cao, B., H. Wang, H. Sun, Y. Zhu, and M. Chen. 2004. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J. Hosp. Infect. 57:112-118.
6. Cardoso, O., J. C. Sousa, R. Leitao, and L. Peixe. 1999. Carbapenem-hydrolising beta-lactamase from clinical isolates of Pseudomonas aeruginosa in Portugal. J. Antimicrob. Chemother. 44:135.
7. Colom, K., A. Fdz-Aranguiz, E. Suinaga, and R. Cisterna. 1995. Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group 1 beta-lactamases in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 14:964-971.
8. Defez, C., P. Fabbro-Peray, N. Bouziges, A. Gouby, A. Mahamat, J. P. Daures, and A. Sotto. 2004. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J. Hosp. Infect. 57:209-216.
9. Donskey, C. J., T. K. Chowdhry, M. T. Hecker, C. K. Hoyen, J. A. Hanrahan, A. M. Hujer, R. A. Hutton-Thomas, C. C. Whalen, R. A. Bonomo, and L. B. Rice. 2000. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343:1925-1932.
10. El Amari, E. B., E. Chamot, R. Auckenthaler, J. C. Pechere, and C. Van Delden. 2001. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin. Infect. Dis. 33:1859-1864.
11. Franceschini, N., B. Caravelli, J. D. Docquier, M. Galleni, J. M. Frere, G. Amicosante, and G. M. Rossolini. 2000. Purification and biochemical characterization of the VIM-1 metallo-β-lactamase. Antimicrob. Agents Chemother. 44:3003-3007.
12. Fridkin, S. K., and R. P. Gaynes. 1999. Antimicrobial resistance in intensive care units. Clin. Chest Med. 20:303-316.
13. Gales, A. C., L. C. Menezes, S. Silbert, and H. S. Sader. 2003. Dissemination in distinct Brazilian regions of an epidemic carbapencm-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. J. Antimicrob. Chemother. 52:699-702.
14. Gales, A. C., A. O. Reis, and R. N. Jones. 2001. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39:183-190.
15. Garner, J. S., W. R. Jarvis, T. G. Emori, T. C. Koran, and J. M. Hughes. 1988. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 16:128-140.
16. IMP-7. Antimicrob. Agents Chemother. 46:255-258.
17. Harris, A. D., T. B. Karchmer, Y. Carmeli, and M. H. Samore. 2001. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis. 32:1055-1061.
18. Harris, A. D., E. Perencevich, M. C. Roghmann, G. Morris, K. S. Kaye, and J. A. Johnson. 2002. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob. Agents Chemother. 46:854-858.
19. Harris, A. D., M. H. Samore, M. Lipsitch, K. S. Kaye, E. Perencevich, and Y. Carmeli. 2002. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin. Infect. Dis. 34:1558-1563.
20. Harris, A. D., D. Smith, J. A. Johnson, D. D. Bradham, and M. C. Roghmann. 2002. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin. Infect. Dis. 34:340-345.
21. Hawkey, P. M., J. Xiong, H. Ye, H. Li, and F. H. M'Zali. 2001. Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol. Lett. 194:53-57.
22. Kiska, D. L., and P. H. Gilligan. 1999. Pseudomonas, p. 516-526. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.
23. IMP-containing Pseudomonas aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes. Antimicrob. Agents Chemother. 43:890-901.
24. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
25. Livermore, D. M. 2003. Bacterial resistance: origins, epidemiology, and impact. Clin. Infect. Dis. 36:S11-S23.
26. Livermore, D. M., and N. Woodford. 2000. Carbapenemases: a problem in waiting? Curr. Opin. Microbiol. 3:489-495.
27. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. Niederman, M. S. 2001. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit. Care Med. 29:N114-N120.
29. Padoveze, M. C., P. Trabasso, and M. L. Branchini. 2002. Nosocomial infections among HIV-positive and HIV-negative patients in a Brazilian infectious diseases unit. Am. J. Infect. Control 30:346-350.
30. Paladine, J. A., J. L. Sunderlin, C. S. Price, and J. J. Schentag. 2002. Economic consequences of antimicrobial resistance. Surg. Infect. (Larchmont) 3:259-267.
31. Paramythiotou, E., J. C. Lucet, D. Timsit, D. Vanjak, C. Paugam-Burtz, J. L. Trouillet, S. Belloc, N. Kassis, A. Karabinis, and A. Andremont. 2004. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 38:670-677.
32. Paterson, D. L. 2002. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin. Infect. Dis. 34:1564-1567.
33. Peleg, A. Y., C. Franklin, J. Bell, and D. W. Spelman. 2004. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. J. Antimicrob. Chemother. 54:699-700.
34. Pellegrino, F. L. P. C., L. M. Teixeira, M. da Glória Siqueira Carvalho, S. A. Nouér, M. P. de Oliveira, J. L. M. Sampaio, A. D'Ávila Freitas, A. L. Pires Ferreira, E. de Lourdes Teixeira Amorim, L. W. Riley, and B. M. Moreira. 2002. Occurrence of a multidrug-resistant Pseudomonas aeruginosa clone in different hospitals in Rio de Janeiro, Brazil. J. Clin. Microbiol. 40:2420-2424.
35. SPM-1-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Rccife, Brazil. Antimicrob. Agents Chemother. 48:1406-1409.
36. Richard, P., R. Le Floch, C. Chamoux, M. Pannier, E. Espaze, and H. Richet. 1994. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J. Infect. Dis. 170:377-383.
37. VIM-7, an evolutionarily distinct metallo-β-laetamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 48:329-332.
38. Troillet, N., M. H. Samore, and Y. Carmeli. 1997. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin. Infect. Dis. 25:1094-1098.
39. Trouillet, J. L., A. Vuagnat, A. Combes, N. Kassis, J. Chastre, and C. Gibert. 2002. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to pipenicillin-resistant versus piperacillin-susceptible organisms. Clin. Infect. Dis. 34:1047-1054.
40. Tysall, L., M. W. Stockdale, P. R. Chadwick, M. F. Palepou, K. J. Towner, D. M. Livermore, and N. Woodford. 2002. IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. J. Antimicrob. Chemother. 49:217-218.
41. Van, J.-J., P.-R. Hsueh, W.-C. Ko, K.-T. Luh, S.-H. Tsai, H.-M. Wu, and J.-J. Wu. 2001. Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob. Agents Chemother. 45:2224-2228.